8-K: OnKure Therapeutics Launches ATM Equity Offering

OnKure Therapeutics, Inc. has entered into a sales agreement with Leerink Partners LLC to establish an 'at-the-market' equity offering program for its Class A common stock.

Summary

• OnKure Therapeutics, Inc. (the Company) signed a sales agreement with Leerink Partners LLC on November 6, 2025, to sell shares of its Class A common stock through an 'at-the-market' (ATM) offering program.
• Leerink Partners LLC will act as the sales agent, selling shares from time to time on the Nasdaq Global Market or other trading markets.
• The Company retains discretion to set parameters for sales, including maximum number or dollar amount of shares, time periods, daily limits, and minimum prices.
• Leerink Partners LLC will receive compensation of up to 3.0% of the gross proceeds from the sales of Placement Shares.
• The Company has no obligation to sell any shares and can suspend sales at any time.
• The Placement Shares will be offered and sold pursuant to the Company's shelf registration statement on Form S-3, which is to be filed and become effective on November 6, 2025.
• As of November 5, 2025, the aggregate market value of the Company's non-affiliate common equity was approximately $15,986,792, calculated using the October 27, 2025, price and September 30, 2025, shares outstanding.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an ATM offering provides beneficial financial flexibility and access to capital, it also introduces the potential for shareholder dilution and possible downward pressure on the stock price, balancing out the positive aspects.

Positives

• The ATM offering provides OnKure Therapeutics with financial flexibility to raise capital opportunistically based on market conditions.
• The Company has no obligation to sell shares, allowing it to control the timing and amount of capital raised.
• This method can be a more cost-effective way to raise capital compared to traditional underwritten offerings, reducing upfront expenses.

Negatives

• The offering could lead to dilution for existing shareholders as new shares are sold into the market.
• The sale of shares through an ATM program may exert downward pressure on the Company's stock price, especially if sales are frequent or substantial.
• Leerink Partners LLC will receive a commission of up to 3.0% of gross proceeds, reducing the net funds received by the Company.

Risks

• There is no assurance that Leerink Partners LLC will be successful in selling Placement Shares, impacting the Company's ability to raise desired capital.
• The Company is solely responsible for ensuring compliance with offering size limitations, including those related to its Form S-3 eligibility and authorized capital.
• Market conditions, trading suspensions, banking moratoriums, or significant geopolitical/economic changes could lead to the termination of the sales agreement by the Agent.
• The Company must ensure it is not in possession of material non-public information when requesting sales of Placement Shares, to avoid legal and regulatory issues.
• Failure to maintain Form S-3 eligibility could restrict the Company's ability to use this offering mechanism.

Future Outlook

The Company intends to use the 'at-the-market' offering program to raise capital from time to time, providing ongoing financial flexibility. The proceeds are expected to be used as described in the prospectus, typically for general corporate purposes, research and development, or working capital.

Management Comments

• Nicholas A. Saccomano, President and Chief Executive Officer, signed the Sales Agreement on behalf of OnKure Therapeutics, Inc.
• Jason Leverone, Chief Financial Officer, signed the Form 8-K on behalf of OnKure Therapeutics, Inc.

Industry Context

ATM offerings are a common capital-raising tool for biotechnology and pharmaceutical companies, particularly those in development stages, as they provide a flexible and efficient way to fund ongoing research, clinical trials, and general corporate expenses without the immediate pricing pressure and extensive marketing efforts of a traditional underwritten public offering. This allows companies like OnKure to tap into the market as needed, aligning capital raises with specific milestones or favorable market conditions.

Comparison to Industry Standards

• The agent compensation of up to 3.0% is within the typical range for ATM offerings in the biotechnology sector, which can vary based on market conditions, deal size, and the agent's role.
• The use of a Form S-3 shelf registration statement for an ATM program is standard practice for eligible public companies, providing a streamlined process for future offerings.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for dilution due to the issuance of new shares, which could impact per-share earnings and stock value. However, the offering provides the Company with capital for operations, potentially supporting long-term growth.
• Creditors: Improved liquidity and access to capital may enhance the Company's financial stability, potentially reducing credit risk.
• Employees: Access to capital can support ongoing operations, research, and development, which may contribute to job security and growth opportunities within the Company.

Next Steps

• The Company will file a prospectus supplement with the SEC under Rule 424(b) setting forth details of shares sold, net proceeds, and agent compensation.
• The Company will continue to comply with all SEC and Nasdaq reporting and listing requirements.
• The Company will make generally available an earnings statement covering a 12-month period within 15 months after the end of the current fiscal quarter.

Key Dates

Keywords

At-the-market offering, ATM, Equity offering, Capital raise, Common stock, SEC filing, Form S-3, Dilution, Financial flexibility, Leerink Partners